益生菌联合膳食纤维治疗非酒精性脂肪肝的临床研究

Clinical study on probiotics and dietary cellulose tablets in the treatment of non-alcoholic fatty liver

  • 摘要: 目的 观察双歧杆菌三联活菌胶囊联合膳食纤维片治疗非酒精性脂肪肝(NAFLD)的临床疗效。 方法 选取98例确诊NAFLD患者为研究对象,采用简单随机分组法分为对照组(n=49)和研究组(n=49)。所有NAFLD患者均接受保肝治疗和健康宣教等基础干预措施,对照组给予膳食纤维片治疗,研究组给予双歧杆菌三联活菌胶囊联合膳食纤维片治疗, 2组均持续治疗3个月。检测并比较2组肝功能指标[丙氨酸转氨酶(ALT)、天门冬氨酸转氨酶(AST)、谷氨酰转肽酶(γ-GT)], 血清内毒素以及炎症因子[白细胞介素-6(IL-6)、超敏C反应蛋白(hs-CRP)]水平,记录治疗期间不良反应情况。 结果 98例NAFLD患者均成功完成研究。2组治疗3个月血清ALT、AST、γ-GT检测水平均较治疗前显著下降(P<0.05), 研究组治疗3个月上述肝功能指标水平显著低于对照组(P<0.05); 2组治疗3个月后血清内毒素和炎症因子IL-6、hs-CRP检测水平均较治疗前显著下降(P<0.05), 且研究组显著低于对照组(P<0.05); 治疗3个月期间, 2组患者均无身体不适及不良反应,联合用药安全性较好。 结论 双歧杆菌三联活菌胶囊联合膳食纤维片能有效降低NAFLD患者血清内毒素水平,抑制肝细胞炎症反应,改善并保护肝功能。

     

    Abstract: Objective To observe the clinical effect of Bifidobacterium triple viable capsule combined with dietary cellulose in the treatment of non-alcoholic fatty liver(NAFLD). Methods A total of 98 patients with NAFLD were selected as research objects, and were divided into control group(n=49)and study group(n=49)by simple random grouping method. All NAFLD patients received basic intervention measures such as liver protection treatment and health education. The control group was treated with dietary cellulose, and the study group was treated with Bifidobacterium triple viable capsule combined with dietary cellulose tablets. All patients were continuously treated for 3 months. The changes of liver function indexes[alanine aminotransferase(ALT), aspartate aminotransferase(AST), γ-glutamyltranspeptidase(γ-GT)], serum endotoxin as well as inflammatory factors [interleukin-6(IL-6), high sensitivity C reactive protein(hs-CRP)]were detected and compared between the two groups. The occurrence of adverse reactions was recorded during the treatment. Results All the 98 patients with NAFLD successfully completed the study. The serum ALT, AST and γ-GT levels at 3 months after treatment in the two groups were significantly lower than those before treatment(P<0.05). The above liver function indexes in the study group were significantly lower than those in the control group(P<0.05); the levels of serum endotoxin, IL-6 and hs-CRP at 3 months after treatment in the two groups were significantly lower than those before treatment(P<0.05), and were lower in the study group compared with the control group(P<0.05). There were no obvious adverse reactions or physical discomfort in the two groups during 3-month treatment, and combination of two drugs had higher safety. Conclusion Bifidobacterium triple viable capsule combined with dietary cellulose tablets can effectively reduce the level of serum endotoxin and inhibit the inflammatory response of hepatocytes- in NAFLD patients, and play a better role in the protection and improvement of liver function.

     

/

返回文章
返回